Can Novo Nordisk’s New Semaglutide and Obesity Pipeline Data at EASD 2025 Redefine ‘Food Noise’ Control, Body Composition, and Cardiovascular Outcomes?

Key Highlights:

• Real-world INFORM study shows semaglutide reduces ‘food noise’—a critical driver of overeating.
• STEP UP clinical trial demonstrates semaglutide’s effect on control of eating, body composition, and proximal muscle strength.
• REACH study shows superiority of Ozempic® versus dulaglutide in preventing cardiovascular events including heart attack and stroke.
• Next-generation therapies (cagrilintide, CagriSema, amycretin) highlight Novo Nordisk’s advancing obesity pipeline.

Scientific Momentum at EASD 2025
Novo Nordisk will present 35 abstracts across its diabetes and obesity portfolio at the European Association for the Study of Diabetes (EASD) Annual Meeting (Vienna, Sept 15–19, 2025). These include clinical and real-world data on semaglutide, highlighting broad health benefits, the widest approved indications, and its established weight loss effect.

Semaglutide: Redefining Eating Control and Cardiometabolic Outcomes

• The INFORM study (US real-world data) confirms semaglutide’s impact on reducing intrusive “food noise.”
• STEP UP trial results demonstrate improved eating control, favorable body composition changes, and preserved muscle strength.
• REACH head-to-head real-world trial shows Ozempic®’s superiority to dulaglutide in reducing cardiovascular events.

Pipeline Innovations Beyond Semaglutide

• CagriSema: Combined semaglutide and cagrilintide delivers superior outcomes in type 2 diabetes and obesity.
• Cagrilintide Monotherapy (REDEFINE 1) demonstrates efficacy as a next-gen obesity treatment.
• Amycretin: Early-phase data show promise of this novel dual GLP-1 and amylin receptor agonist.

Regulatory and Industry Impact
Semaglutide, already supported by over 33 million patient-years of exposure since 2018, continues to anchor Novo Nordisk’s metabolic disease franchise. These new findings strengthen its positioning not just in type 2 diabetes and obesity but also in cardiovascular protection and liver disease, expanding the therapy’s relevance in global public health.

About Novo Nordisk: www.novonordisk.com
Novo Nordisk, founded in 1923 and headquartered in Denmark, is a global healthcare leader in diabetes and obesity. With ~78,400 employees in 80 countries, Novo Nordisk markets products in ~170 countries. The company’s purpose is to defeat serious chronic diseases through scientific breakthroughs, expanded access, and prevention strategies.